Characteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors: A Single-Institution Experience
: The clinical outcomes of our real-world patients are similar to those reported in previous clinical trials. In addition, metastatic site distribution was independently prognostic for survival outcomes and may support baseline risk stratification at the time of PARPi initiation. Further studies of predictive markers of response and resistance, as well as sequencing with platinums and combinations with other targeted agents, are needed to optimize the benefits of PARPi in this patient population.
Authors
- Fatma Nihan Akkoç Mustafayev (ORCID: https://orcid.org/0000-0001-7024-4156)
- Katharina Schlacher (ORCID: https://orcid.org/0000-0001-7226-6391)
- Constance T. Albarracin (ORCID: https://orcid.org/0000-0002-1236-7315)
- Mark F. Munsell (ORCID: https://orcid.org/0000-0001-9654-4958)
- Clinton Yam (ORCID: https://orcid.org/0000-0002-0809-0851)
- Rachel M. Layman (ORCID: https://orcid.org/0000-0002-8663-0331)
- Zamal Ahmed (ORCID: https://orcid.org/0000-0003-3400-6577)
- Angelica M. Gutierrez‐Barrera (ORCID: https://orcid.org/0000-0002-8582-8186)
- Elena Fountzilas (ORCID: https://orcid.org/0000-0002-4884-2544)
- John A Tainer
- Banu K. Arun
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-04-16
- DOI
- https://doi.org/10.3390/cancers18081258
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Prevention and Research Institute of Texas